Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FROVATRIPTAN SUCCINATE vs ELETRIPTAN HYDROBROMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial extracerebral blood vessels and inhibits nociceptive trigeminal nerve transmission.
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibition of trigeminal nerve transmission.
Acute treatment of migraine with or without aura in adults
Acute treatment of migraine with or without aura in adults
2.5 mg orally once, may repeat after 2 hours if needed; maximum 7.5 mg in 24 hours.
40 mg orally once, may repeat after 2 hours if headache recurs; maximum 80 mg/day.
Terminal elimination half-life is approximately 4-5 hours (range 3-6 hours). This relatively short half-life supports its use for acute migraine treatment, though it may allow for repeat dosing within 24 hours if necessary.
Terminal elimination half-life is approximately 4-5 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged up to 8 hours. The half-life supports a clinical duration suitable for acute migraine treatment, with no accumulation with single doses.
Primarily hepatic via CYP1A2; undergoes oxidative metabolism; some contribution from CYP2D6.
Primarily metabolized by CYP3A4; also minor contribution from CYP2C9, CYP2C19, and CYP2D6.
Primarily hepatic metabolism via CYP1A2; renal excretion accounts for ~10% of unchanged drug. Total recovery in urine and feces is ~90% over 72 hours, with ~30% in urine (mostly metabolites) and ~60% in feces.
Approximately 90% of the dose is eliminated in feces, with less than 10% recovered in urine. Renal excretion accounts for about 9% of total clearance, primarily as unchanged drug. Biliary/fecal elimination is the major route.
Approximately 30% bound to plasma proteins, primarily albumin. Low protein binding suggests minimal displacement interactions.
Approximately 85% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Mean volume of distribution is approximately 2.7 L/kg, indicating extensive extravascular distribution, consistent with its CNS penetration for migraine relief.
Volume of distribution is approximately 1.4 L/kg (range 1.0-2.0 L/kg), indicating extensive distribution into tissues beyond total body water.
Oral bioavailability is approximately 30% due to first-pass metabolism. No other routes are clinically approved; the drug is only available orally.
Oral bioavailability is approximately 50% (range 30-70% due to first-pass metabolism) for the tablet formulation. Absolute bioavailability is moderate due to presystemic clearance.
Contraindicated in severe renal impairment (Cr Cl <15 m L/min). For moderate impairment (Cr Cl 15-29 m L/min), maximum dose 2.5 mg per 24 hours. No adjustment for mild impairment.
No dose adjustment required for mild to moderate renal impairment; contraindicated in severe renal impairment (Cr Cl <10 m L/min).
Contraindicated in moderate to severe hepatic impairment (Child-Pugh class B or C). For mild impairment (Child-Pugh class A), no dose adjustment required.
Contraindicated in severe hepatic impairment (Child-Pugh C); no adjustment for mild to moderate impairment.
Safety and efficacy not established in pediatric patients under 18 years of age.
Not established; safety and efficacy in patients <18 years not studied.
No specific dose adjustment recommended based on age alone, but use with caution due to increased risk of adverse effects (e.g., cardiovascular events) and potential age-related renal impairment.
Use with caution due to potential decreased hepatic/renal function; consider lower starting dose (20 mg).
Not recommended for use in patients with risk factors for coronary artery disease (CAD) unless a cardiovascular evaluation confirms absence of CAD.
No FDA boxed warning.
Serious cardiac events including myocardial ischemia, infarction, and arrhythmias; cerebrovascular events including stroke; serotonin syndrome when coadministered with serotonergic drugs; increases in blood pressure; peripheral vascular ischemia; medication overuse headache; severe hepatic impairment.
Coronary artery vasospasm and ischemic heart disease,Cerebrovascular events (stroke, transient ischemic attack),Life-threatening serotonin syndrome (especially with SSRIs/SNRIs),Hypertensive crisis in patients with uncontrolled hypertension,Risk of myocardial ischemia in patients with risk factors
Ischemic heart disease; history of myocardial infarction; coronary artery vasospasm; uncontrolled hypertension; hemiplegic or basilar migraine; concomitant use with ergotamines or 5-HT1 agonists; severe hepatic impairment; hypersensitivity to frovatriptan.
History of ischemic heart disease or coronary artery vasospasm,Uncontrolled hypertension,Hemiplegic or basilar migraine,Use within 24 hours of another triptan or ergotamine,Concurrent use of MAO inhibitors or within 2 weeks of discontinuation,Severe hepatic impairment (Child-Pugh C)
No specific food interactions. Avoid alcohol as it can exacerbate migraine and increase sedation risk. Grapefruit juice may increase frovatriptan levels due to CYP1A2 inhibition; limit or avoid consumption.
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4, increasing eletriptan exposure and risk of adverse effects. No other significant food interactions reported.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, frovatriptan caused fetal toxicity (decreased fetal weight, increased skeletal variations) at doses ≥50 mg/kg/day (approximately 100 times the MRHD). Increased risk of maternal toxicity (reduced weight gain) at high doses. Potential risk of uterine contractions and reduced uterine blood flow due to vasoconstrictive properties. Use only if potential benefit justifies risk to fetus.
Limited human data; animal studies show no teratogenicity at clinically relevant doses. First trimester: risk cannot be excluded; second/third trimester: no known increased risk. Avoid in third trimester due to possible uterine atony or decreased placental perfusion.
Excreted in rat milk; no human data. M/P ratio unknown. Caution recommended due to potential adverse effects in nursing infants (e.g., vasoconstriction, serotonin syndrome). Decision to breastfeed or discontinue drug should consider importance of drug to mother.
Excreted into breast milk in low amounts (M/P ratio unknown). Relative infant dose estimated at <1% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for irritability and sleep disturbance.
No specific pharmacokinetic studies in pregnancy. Dose adjustment not established; use lowest effective dose. Caution in third trimester due to possible uterine vasoconstriction. Consider alternative therapy if frequent use needed.
No specific dose adjustment recommended; pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce efficacy, but standard dosing remains safe. Consider lowest effective dose.
Frovatriptan has a long half-life (~26 h), making it useful for prolonged migraine attacks or for menstrual migraine prophylaxis when dosed perimenstrually. Onset is slower than other triptans; not ideal for acute severe migraine requiring rapid relief. Contraindicated with MAOIs, potent CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin), and within 24 h of another triptan or ergotamine. Avoid in patients with hemiplegic or basilar migraine, ischemic heart disease, or uncontrolled hypertension.
Eletriptan has higher lipophilicity and longer half-life than sumatriptan, potentially offering better CNS penetration and sustained efficacy. Contraindicated within 24 hours of other triptans or ergotamines. Avoid in patients with severe hepatic impairment (Child-Pugh C) as metabolism is CYP3A4-dependent. Maximum single dose 40 mg; may repeat after 2 hours if no response, but do not exceed 80 mg/day. Onset typically within 30 minutes; if first dose fails, consider alternative therapy for subsequent attacks.
Take frovatriptan at the first sign of a migraine headache, not during the aura or for prevention of typical migraines.,Swallow tablets whole with water; do not crush or chew.,If the headache returns after initial relief, a second dose may be taken after at least 2 hours, with a maximum of 3 tablets per 24 hours.,Do not use frovatriptan if you have taken another triptan or ergotamine within the last 24 hours.,Seek emergency medical attention if you experience chest pain, shortness of breath, irregular heartbeat, or signs of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness).,Avoid alcohol during use as it may worsen headache or increase side effects.,Inform your doctor if you are pregnant, breastfeeding, or have liver or kidney disease.,Do not drive or operate machinery until you know how frovatriptan affects you, as it may cause dizziness or drowsiness.
Take at the first sign of migraine headache, not for prevention.,Do not take more than 80 mg in 24 hours; wait at least 2 hours between doses.,Avoid taking within 24 hours of other triptans or ergotamine medications.,Report chest pain, palpitations, or shortness of breath immediately.,Do not use if you have uncontrolled high blood pressure, coronary artery disease, or history of stroke.,Grapefruit juice may increase drug levels; avoid consumption during treatment.,Swallow tablet whole; do not crush or chew.
"Frovatriptan, a serotonin 5-HT1B/1D receptor agonist used for acute migraine, and chlorpromazine, a first-generation antipsychotic with potent dopamine D2 receptor antagonism, can lead to additive serotonin excess when co-administered due to their combined serotonergic activity. Chlorpromazine also possesses weak serotonin reuptake inhibition properties, increasing the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. Additionally, chlorpromazine may antagonize the vasoconstrictive effects of triptans via alpha-adrenergic blockade, potentially reducing migraine relief efficacy."
"Frovatriptan, a triptan used for migraine, is primarily metabolized by CYP1A2. Clotrimazole, an azole antifungal, inhibits CYP1A2, thereby reducing the clearance of frovatriptan. This can lead to increased systemic exposure to frovatriptan, potentially elevating the risk of triptan-related adverse effects such as serotonin syndrome, coronary vasospasm, and hypertension."
"Coadministration of frovatriptan, a serotonin receptor agonist metabolized primarily by CYP1A2, with simeprevir, a potent CYP3A4 inhibitor and weak CYP1A2 inducer, may result in reduced clearance of simeprevir due to competitive inhibition of CYP3A4 by frovatriptan or its metabolites. This interaction can lead to increased simeprevir plasma concentrations, elevating the risk of hepatotoxicity, photosensitivity reactions, and QT prolongation. Conversely, frovatriptan exposure is not significantly altered as its metabolism via CYP1A2 is minimally affected by simeprevir."
"Eletriptan, a 5-HT1B/1D receptor agonist used for migraine, and ondansetron, a 5-HT3 receptor antagonist antiemetic, both increase serotonergic activity via different mechanisms. Concurrent use may lead to excessive serotonin accumulation, potentially triggering serotonin syndrome, characterized by neuromuscular excitation, autonomic instability, and altered mental status. While the interaction is mechanistically plausible, clinical reports are rare, and caution is advised particularly in patients on multiple serotonergic agents."
"Concomitant use of eletriptan, a 5-HT1B/1D receptor agonist, with maprotiline, a tetracyclic antidepressant that inhibits serotonin reuptake, may result in additive serotonergic effects. This increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients combining these agents require close monitoring for symptoms such as hyperthermia, clonus, hyperreflexia, and agitation."
"Concomitant use of eletriptan and almotriptan, both triptan-class 5-HT1B/1D receptor agonists, increases the risk of serotonin syndrome and additive vasoconstriction, including coronary vasospasm. Excessive serotonergic activity may lead to neuromuscular excitation, autonomic instability, and altered mental status, while additive arterial vasoconstriction can precipitate severe hypertension or ischemic events, especially in patients with cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FROVATRIPTAN SUCCINATE vs ELETRIPTAN HYDROBROMIDE, answered by our medical review team.
FROVATRIPTAN SUCCINATE is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial extracerebral blood vessels and inhibits nociceptive trigeminal nerve transmission.. ELETRIPTAN HYDROBROMIDE is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibition of trigeminal nerve transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FROVATRIPTAN SUCCINATE and ELETRIPTAN HYDROBROMIDE depend on the specific clinical indication. These are both 5-HT1 Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FROVATRIPTAN SUCCINATE is: 2.5 mg orally once, may repeat after 2 hours if needed; maximum 7.5 mg in 24 hours.. The standard adult dose of ELETRIPTAN HYDROBROMIDE is: 40 mg orally once, may repeat after 2 hours if headache recurs; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining FROVATRIPTAN SUCCINATE and ELETRIPTAN HYDROBROMIDE. The risk or severity of adverse effects can be increased when Eletriptan is combined with Frovatriptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. FROVATRIPTAN SUCCINATE is classified as Category D/X. Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, frovatriptan caused fetal toxicity (decreased fetal weight, increased skeletal varia. ELETRIPTAN HYDROBROMIDE is classified as Category D/X. Limited human data; animal studies show no teratogenicity at clinically relevant doses. First trimester: risk cannot be excluded; second/third trimester: no known increased risk. A. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.